EGFR-TKIs and radiation therapy (RT) are the principal treatment for patients with brain
metastases (BM) and EGFR mutant NSCLC. However, the optimal use of brain RT for …

Background The prognosis of non-small-cell lung cancer (NSCLC) with brain metastases is
very poor. Currently, therapeutic methods for this patient population include whole-brain …

Brain metastases (BMs) cause morbidity and mortality in patients with non‐small cell lung
cancer (NSCLC). The optimal management of epidermal growth factor receptor (EGFR) …

Background Non-small cell lung cancer (NSCLC) with brain metastases (M) had a poor
prognosis. Whole brain irradiation (WBI) is a standard of care for this critical medical …

Over the past decade, the advent of tyrosine kinase inhibitors (TKIs) has revolutionized the
management of patients with non–small-cell lung cancer (NSCLC) harboring epidermal …

Simple Summary Targeted therapies have emerged as newer systemic options for certain
cancers. EGFR-directed Tyrosine Kinase Inhibitors (EGFR-TKIs), which have several …

Objectives Whole-brain radiation therapy (WBRT) and epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) are both treatment options for EGFR-mutated non …

Background It has been confirmed that epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) presented better efficacy than brain radiotherapy (brain RT) in the …

Brain metastases and/or leptomeningeal disease (LMD) with associated central nervous
system (CNS) metastases are known complications of advanced epidermal growth factor …

Purpose Icotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors. A phase II study was conducted to evaluate the efficacy and safety of …